NCT07306884

Brief Summary

Diabetic peripheral neuropathy causes pain, sensory loss, and foot risk; multimodal assessment enables earlier diagnosis and improved patient management.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
9mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress32%
Jan 2026Feb 2027

First Submitted

Initial submission to the registry

September 25, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 29, 2025

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

December 29, 2025

Status Verified

December 1, 2025

Enrollment Period

1 year

First QC Date

September 25, 2025

Last Update Submit

December 13, 2025

Conditions

Keywords

Diabete MellitusPeripheral neuropathyNeurophysiological studiesNerve ultrasoundautomatic assessment

Outcome Measures

Primary Outcomes (1)

  • Sensitivity of nerve conduction studies for diagnosing diabetic peripheral neuropathy

    Percentage of participants with clinically diagnosed diabetic peripheral neuropathy who have abnormal nerve conduction study results (reduced amplitude and/or reduced conduction velocity) at the baseline visit.

    Baseline (single study visit)

Secondary Outcomes (1)

  • Correlation between tibial nerve cross-sectional area and tibial motor conduction velocity

    Baseline (single study visit)

Study Arms (3)

Diabetic patients with symptomatic peripheral neuropathy.

OTHER
Diagnostic Test: Nerve conduction studyDiagnostic Test: Nerve ultrasound

Diabetic without any clinical features nor complaints of peripheral neuropathy

OTHER
Diagnostic Test: Nerve conduction studyDiagnostic Test: Nerve ultrasoundDiagnostic Test: Autonomic assessment

Healthy individuals.

OTHER
Diagnostic Test: Nerve conduction studyDiagnostic Test: Nerve ultrasoundDiagnostic Test: Autonomic assessment

Interventions

Nerve ultrasoundDIAGNOSTIC_TEST

High-resolution ultrasound (HRUS) is a non-invasive imaging tool that allows structural evaluation of peripheral nerves. It can measure cross-sectional area (CSA), visualize fascicular pattern, and detect nerve enlargement or structural abnormalities. In diabetic peripheral neuropathy, HRUS provides complementary information to functional tests and may identify early or subclinical changes.

Diabetic patients with symptomatic peripheral neuropathy.Diabetic without any clinical features nor complaints of peripheral neuropathyHealthy individuals.
Autonomic assessmentDIAGNOSTIC_TEST

Autonomic testing provides insight into small-fiber and autonomic nervous system function, often impaired early in diabetic peripheral neuropathy. Heart rate variability (HRV) during deep breathing and postural change is a simple, non-invasive method to detect cardiovascular autonomic dysfunction

Diabetic without any clinical features nor complaints of peripheral neuropathyHealthy individuals.
Nerve conduction studyDIAGNOSTIC_TEST

Nerve conduction studies (NCS) are widely regarded as the gold standard for evaluating large-fiber peripheral nerve function. They measure conduction velocity, latency, and amplitude, providing objective evidence of axonal loss or demyelination. While highly specific, NCS often detect abnormalities only in established diabetic peripheral neuropathy, limiting their sensitivity for early or subclinical disease.

Diabetic patients with symptomatic peripheral neuropathy.Diabetic without any clinical features nor complaints of peripheral neuropathyHealthy individuals.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 18-75 years with type 1 or type 2 diabetes (with or without diabetic peripheral neuropathy), and age and sex-matched healthy controls

You may not qualify if:

  • Other causes of neuropathy (e.g., CIDP, trauma, toxins, vitamin deficiencies), advanced renal failure,thyroid disease,chronic alcohol use, pregnancy,
  • presence of implanted cardiac devicesthat may interfere with autonomic testing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurology, Faculty of Medicine,Assiut university

Asyut, Asyut Governorate, 71511, Egypt

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetic NeuropathiesPeripheral Nervous System Diseases

Interventions

Nerve Conduction Studies

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesNeuromuscular DiseasesNervous System DiseasesDiabetes Complications

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, NeurologicalDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Study Officials

  • Nageh Fouly

    Department of Neurology , Assiut University, Egypt

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident at Neurology and Psychiatry Department, Assiut University

Study Record Dates

First Submitted

September 25, 2025

First Posted

December 29, 2025

Study Start

January 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

December 29, 2025

Record last verified: 2025-12

Locations